USPTO serial 88676007
VYDURO
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- KEATING, SHANNON B
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VYDURO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
BIOHAVEN PHARMACEUTICAL IRELAND DAC
Ringaskiddy, IE
Other trademarks owned by BIOHAVEN PHARMACEUTICAL IRELAND DAC
Biohaven Pharmaceutical Holding Company Ltd.
New Haven, CT
Other trademarks owned by Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd.
New Haven, CT
Other trademarks owned by Biohaven Pharmaceutical Holding Company Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrea Christensen
Andrea Christensen Pfizer Inc.235 East 42nd StreetNew York, NY 10017UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), huntington's disease, lewy body dementia, frontotemporal dementia, vascular dementia, parkinson's disease, cognitive impairment of aging, progressive multiple sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to nmda receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, post traumatic stress disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, obsessive compulsive disorder (OCD), hoarding, trichotillomania, eating disorders, generalized anxiety disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, attention deficit disorder (ADD), pervasive developmental disorders (PDD), asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use; all of the foregoing specifically excluding medicated and pharmaceutical preparations and substances for the treatment or management of respiratory diseases and disorders | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BIOHAVEN PHARMACEUTICAL IRELAND DAC
- Other trademarks owned by Biohaven Pharmaceutical Holding Company Ltd.
- Other trademarks owned by Biohaven Pharmaceutical Holding Company Ltd.
- Other trademarks in Class 005
- Similar marks named VYDURO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 14, 2023 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Mar 14, 2023 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Mar 13, 2023 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Oct 27, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 27, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 27, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 27, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 27, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 24, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 22, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 22, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 22, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 13, 2022 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 7, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 5, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Apr 5, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Apr 5, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 7, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 5, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 5, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 5, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 31, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 29, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 29, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 29, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 6, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 27, 2020 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Mar 11, 2020 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Feb 18, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 18, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 29, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 10, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 7, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 4, 2019 | NWAP | NEW APPLICATION ENTERED | — |